Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while ProShares UltraPro S&P500 trades at $154.81 (market cap $5.55B). The key difference: ProShares UltraPro S&P500 is far larger — about 407.5× Citius Pharmaceuticals Inc's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and ProShares UltraPro S&P500 for 29 Days on average.
| CTXR | UPRO | |
|---|---|---|
Market Cap | $13.62M | $5.55B |
Volume | 132,438 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $157.66 |
52-Week Low | $0.48 | $89.29 |
Typical Hold Time | 16 Days | 29 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
UPRO trades at $155.21, down 0.77% for the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces resistance near $156-$160 with support at $151-$147. Recent news highlights S&P 500 valuation concerns and projected earnings growth slowdown from 35% in 2026 to 15% in 2027, creating mixed sentiment around leveraged ETF performance.
Outlook remains cautiously optimistic given the bullish technical setup, though leveraged nature amplifies risks from market volatility and earnings growth deceleration. Key opportunities include potential year-end rally patterns, while risks center on concentrated market exposure and macroeconomic headwinds affecting the underlying index performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
